HCID 54589424, compound → HCID 54761677, compound

Participants

Reaction Steps

N-(4-(3-(5-tert-Butylisoxazol-3-yl)ureido)phenyl)-5-(1-ethylazetidin-3-yloxy)picolinamide (13 mg, 34%) was prepared as an off-white powder using a procedure analogous to that described in Example 2, substituting 5-(azetidin-3-yloxy)-N-(4-(3-(5-tert-butylisoxazol-3-yl)ureido)phenyl)picolinamide hydrochloride from Step 2 of this example for N-(4-(3-(5-tert-butylisoxazol-3-yl)ureido)phenyl)-4-(piperidin-4-yloxy)picolinamide hydrochloride used in Example 2. LC-MS (ESI) m/z 479 (M+H)+; 1H NMR (300 MHz, DMSO-d6) δ 10.41 (s, 1H), 9.51 (s, 1H), 8.81 (s, 1H), 8.32 (br. s., 1H), 8.08 (d, J=8.29 Hz, 1H), 7.81 (d, J=8.29 Hz, 2H), 7.49 (d, J=8.85 Hz, 1H), 7.42 (d, J=7.54 Hz, 2H), 6.50 (s, 1H), 4.99 (t, J=4.71 Hz, 1H), 3.61-3.82 (m, 2H), 2.99 (t, J=5.93 Hz, 2H), 2.46 (br. s., 2H), 1.30 (s, 9H), 0.90 (t, J=6.97 Hz, 3H).

Provenance & Evidence